California Couple Get $2 Billion in Roundup Suit
The couple said they used Roundup on their property for more than three decades and were diagnosed with the same type of cancer, non-Hodgkin lymphoma, four years apart. (Source: WebMD Health)
Source: WebMD Health - May 14, 2019 Category: Consumer Health News Source Type: news

$2 Billion Verdict Against Monsanto Is Third to Find Roundup Caused Cancer
A state jury ’ s award for a Northern California couple followed awards in separate cases in March and August, and was the largest by far. (Source: NYT Health)
Source: NYT Health - May 14, 2019 Category: Consumer Health News Authors: PATRICIA COHEN Tags: Defoliants and Herbicides Bayer AG Monsanto Company California Hazardous and Toxic Substances Non-Hodgkin's Lymphoma Decisions and Verdicts Pilliod, Alberta Pilliod, Alva Source Type: news

Couple who suffered the same cancer awarded $2 billion in Roundup trial
A California jury ordered Bayer - which owns Monsanto - to pay Alva and Alberta Pilliod $2 billion in damages after ruling Roundup weedkiller was to blame for their non-Hodgkin's lymphoma. (Source: the Mail online | Health)
Source: the Mail online | Health - May 14, 2019 Category: Consumer Health News Source Type: news

Monsanto Expert: 'No Evidence Of Causal Connection' Between Roundup And Cancer
OAKLAND, Calif. - An expert for Monsanto Co. on May 1 testified that "there is no evidence of a causal association between Roundup and non-Hodgkin's lymphoma," as the glyphosate cancer trial of a California couple continued into its 18th day. The parties say that closing arguments are expected May 7 (Alva Pilliod, et al. v. Monsanto Company, No. RG17862702, Calif. Super., Alameda Co.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - May 8, 2019 Category: Medical Law Source Type: news

N.S. man's Stage 4 cancer is in remission after $900K treatment in Boston
It's too early to know if Stephen Saunders has been cured of non-Hodgkin lymphoma, but he's in remission thanks to a treatment not yet available in Nova Scotia. (Source: CBC | Health)
Source: CBC | Health - May 3, 2019 Category: Consumer Health News Tags: News/Canada/Nova Scotia Source Type: news

EPA says glyphosate, the main ingredient in Roundup, doesn't cause cancer
The announcement comes after two high-profile court cases in which cancer patients claimed Roundup, a popular weedkiller containing glyphosate, caused their non-Hodgkin's lymphoma. Jurors awarded both patients tens of millions of dollars. (Source: CNN.com - Health)
Source: CNN.com - Health - May 1, 2019 Category: Consumer Health News Source Type: news

Science Saturday: New genetic test classifies lymphomas
The current diagnostic tools in a pathologist's arsenal sometimes cannot provide a clear distinction between primary mediastinal large B-cell lymphoma (one of the few lymphomas more common in younger women) and diffuse large B-cell lymphoma, the most common type of non-Hodgkin's lymphoma overall. This may occasionally give rise to diagnostic inaccuracy in routine practice and could leave [...] (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - April 27, 2019 Category: Research Source Type: news

Promising Results in Mice Prompt Human Trial of Novel Lymphoma Vaccine Promising Results in Mice Prompt Human Trial of Novel Lymphoma Vaccine
An in situ vaccine (ISV) combined with immune stimulants and radiotherapy showed efficacy in mice, prompting a phase 1 trial of patients with advanced indolent non-Hodgkin's lymphoma (INHL), researchers say.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 24, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Couple that suffered the same cancer after using Roundup for 30 years tells heartbreaking story
Alva and Alberta Pilliod testified this week that they used Monsanto's Roundup for 30 years before they both developed non-Hodgkins lymphoma. They say the weedkiller caused it. (Source: the Mail online | Health)
Source: the Mail online | Health - April 20, 2019 Category: Consumer Health News Source Type: news

Lenalidomide Plus Rituximab Ups Response in Relapsed Indolent Lymphoma Lenalidomide Plus Rituximab Ups Response in Relapsed Indolent Lymphoma
In patients with relapsed or refractory indolent non-Hodgkin lymphoma, adding lenalidomide to rituximab improves response, according to a placebo-controlled trial.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 4, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Researchers discover how tumor-killing immune cells attack lymphomas in living mice
(Rockefeller University Press) In a study that will be published April 1 in the Journal of Experimental Medicine, researchers from the Institut Pasteur and INSERM reveal that chimeric antigen receptor (CAR) T cells can induce tumor regression by directly targeting and killing cancer cells, uncovering new details of how these immune cells work and how their effectiveness could be improved in the treatment of non-Hodgkin's lymphoma and other B cell cancers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 1, 2019 Category: Cancer & Oncology Source Type: news

California Man Awarded $ 80 Million in Roundup Lawsuit
Jury previously found Roundup was a significant factor in plaintiff's non - Hodgkin lymphoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 29, 2019 Category: Cancer & Oncology Tags: Oncology, Pathology, Institutional, Source Type: news

Bayer ordered to pay $81M in Roundup cancer case
A federal jury has ordered Bayer to pay $81 million to a California man who said his use of the company's Roundup weedkiller caused him to develop cancer. The ruling is the latest against Bayer involving Roundup, which was developed by St. Louis-based Monsanto before the company was acquired by Bayer last year for $62.5 billion. A San Francisco jury said Wednesday that the company is liable for the man's non-Hodgkin lymphoma, according to Reuters. Edwin Hardeman was awarded $5.9 million in compensatory… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 27, 2019 Category: Pharmaceuticals Authors: Vince Brennan Source Type: news

Bayer ordered to pay $81M in Roundup cancer case
A federal jury has ordered Bayer to pay $81 million to a California man who said his use of the company's Roundup weedkiller caused him to develop cancer. The ruling is the latest against Bayer involving Roundup, which was developed by St. Louis-based Monsanto before the company was acquired by Bayer last year for $62.5 billion. A San Francisco jury said Wednesday that the company is liable for the man's non-Hodgkin lymphoma, according to Reuters. Edwin Hardeman was awarded $5.9 million in compensatory… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 27, 2019 Category: Biotechnology Authors: Vince Brennan Source Type: news

Jury rules Monsanto IS liable for man's cancer after his years using Roundup
Edwin Hardeman of Santa Rosa, California, has non-Hodgkin's lymphoma, a cancer of the immune system, after using Roundup to kill poison oak on his 56-acre property over 30 years. (Source: the Mail online | Health)
Source: the Mail online | Health - March 27, 2019 Category: Consumer Health News Source Type: news

Bellwether Glyphosate Cancer Trial Heads To Phase 2 To Determine Liability
SAN FRANCISCO - Phase 2 of the federal bellwether glyphosate cancer trial in California started March 20, after a jury the first phase found that the chemical, which is the active ingredient in Monsanto Co.'s herbicide Roundup, was "a substantial factor" in causing the plaintiff's non-Hodgkin lymphoma (NHL) (In re: Roundup Products Liability Litigation, MDL No. 2741, N.D. Calif.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - March 26, 2019 Category: Medical Law Source Type: news

Glyphosate A 'Substantial Factor' In Causing Cancer, Jury Says; Trial Continues
SAN FRANCISCO - A jury in a federal bellwether glyphosate cancer trial in California on March 19 found that the chemical, which is the active ingredient in Monsanto Co.'s herbicide Roundup, was "a substantial factor" in causing the plaintiff's non-Hodgkin lymphoma. Phase 2 of the trial, to determine liability and damages, is slated to begin March 20 (In re: Roundup Products Liability Litigation, MDL No. 2741, N.D. Calif.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - March 26, 2019 Category: Medical Law Source Type: news

Study: People Exposed To Glyphosate Have Increased Risk Of Cancer
LONDON - A study published in the International Journal of Epidemiology on March 18 found that there was an elevation of risk for non-Hodgkin lymphoma (NHL) in people who were exposed to glyphosate, the active ingredient in the herbicide Roundup. (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - March 26, 2019 Category: Medical Law Source Type: news

FDA Scrambles to Prevent Shortages Amid Sterilization Shutdowns
Shutdowns of two facilities that use ethylene oxide to sterilize medical devices have raised concern about potential shortages in the medtech industry because this is such a popular sterilization method for medical devices. Ethylene oxide (EtO) is a flammable, colorless gas used to make a range of products. EtO also is used to sterilize equipment and plastic devices that cannot be sterilized by steam, such as medical equipment. In fact, about half of all sterilized medical devices undergo sterilization using this gas. According to the EPA, long-term exposure to EtO can irritate the eyes,...
Source: MDDI - March 26, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Sterilization Regulatory and Compliance Source Type: news

Watch where you spray: Study reveals high pesticide exposure is linked to olfactory impairment in aging farmers
(Natural News) Some of the dangers of pesticide exposure are painfully obvious – just ask the many people suffering from non-Hodgkin lymphoma after years of exposure to glyphosate. However, some negative effects are far more insidious, sneaking up on people so slowly that they don’t even make the connection to pesticide exposure. Case in point:... (Source: NaturalNews.com)
Source: NaturalNews.com - March 22, 2019 Category: Consumer Health News Source Type: news

Study: Antiretroviral therapy crucial in preventing non-Hodgkin lymphoma
A new study out of the Yale School of Public Health underscores the importance of T-cell count and viral load in developing cancer among those with HIV/AIDS. (Source: Yale Science and Health News)
Source: Yale Science and Health News - March 20, 2019 Category: Universities & Medical Training Source Type: news

Jury finds Monsanto's Roundup weed killer contributed to man's cancer
For the second time, a jury has found Monsanto's Roundup weed killer played a role in causing cancer. Tuesday's unanimous decision determined Roundup caused or was a "substantial factor" in causing 70-year-old Edwin Hardeman's non-Hodgkin's lymphoma. Anna Werner reports. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - March 20, 2019 Category: Consumer Health News Source Type: news

Monsanto Weedkiller Roundup Was ‘ Substantial Factor ’ in Causing Man ’ s Cancer, Jury Says
The finding was the first verdict from a federal jury in thousands of similar cases against the company. (Source: NYT Health)
Source: NYT Health - March 20, 2019 Category: Consumer Health News Authors: MIHIR ZAVERI Tags: Hardeman, Edwin Non-Hodgkin's Lymphoma Pesticides Defoliants and Herbicides Hazardous and Toxic Substances Suits and Litigation (Civil) Monsanto Company Bayer AG Source Type: news

Jury finds Monsanto's Roundup caused another man's cancer
It's the second verdict finding the active ingredient, glyphosate, led to non-Hodgkin's lymphoma in a California man (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - March 20, 2019 Category: Consumer Health News Source Type: news

Jury finds Bayer ’s Roundup as factor in cancer case
A federal jury in San Francisco ruled Tuesday that the weedkiller Roundup, a product developed by Monsanto that was acquired by Bayer, played a significant role in a man ’s cancer.  Edwin Hardeman, a California resident, used the weedkiller in his yard, and the jury found that the exposure to Roundup caused him to develop non-Hodgkin lymphoma, according to the Wall Street Journal. Now the case moves into the next phase for jurors to decide whether the Monsanto unit of Bayer is liable, which could… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 20, 2019 Category: American Health Authors: Vince Brennan Source Type: news

Jury finds Bayer ’s Roundup as factor in cancer case
A federal jury in San Francisco ruled Tuesday that the weedkiller Roundup, a product developed by Monsanto that was acquired by Bayer, played a significant role in a man ’s cancer.  Edwin Hardeman, a California resident, used the weedkiller in his yard, and the jury found that the exposure to Roundup caused him to develop non-Hodgkin lymphoma, according to the Wall Street Journal. Now the case moves into the next phase for jurors to decide whether the Monsanto unit of Bayer is liable, which could… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 20, 2019 Category: Biotechnology Authors: Vince Brennan Source Type: news

Jury rules Roundup was a 'substantial factor' in causing ANOTHER man's cancer
Edwin Hardeman, 70, of Santa Rosa, California, has non-Hodgkin's lymphoma, a cancer of the immune system after using the weed killer in his garden for 30 years. (Source: the Mail online | Health)
Source: the Mail online | Health - March 20, 2019 Category: Consumer Health News Source Type: news

Blogger, 22, battling cancer reveals she is in remission
Ashleigh Rimmer, of Colne in Lancashire, was told last July she had a form of blood cancer called Non-Hodgkin lymphoma. She announced her good news in her latest blog post. (Source: the Mail online | Health)
Source: the Mail online | Health - March 8, 2019 Category: Consumer Health News Source Type: news

Reproductive Factors, Hormone Use, and Risk of B-Cell NHL Reproductive Factors, Hormone Use, and Risk of B-Cell NHL
This study investigated the roles of reproductive factors and exogenous hormone use in risk of B-cell non-Hodgkin lymphoma.American Journal of Epidemiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 26, 2019 Category: Consumer Health News Tags: Internal Medicine Journal Article Source Type: news

Oral Duvelisib Potential New Option for Indolent Non-Hodgkin Lymphoma
The DYNAMO study demonstrated that the oral PI3K gamma inhibitor duvelisib produced an overall response rate in patients with heavily pretreated indolent non-Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - February 26, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Glyphosate exposure found to hike non-Hodgkin lymphoma risk by 41% ... and this deadly weed killer chemical inundates our food supply
(Natural News) Natural News has been warning for years that glyphosate – the primary ingredient in Roundup, the world’s most widely used weed killer – causes cancer. Though studies were published in peer-reviewed journals confirming this link, Monsanto was able to use its massive political clout and almost bottomless funds to tear these studies apart... (Source: NaturalNews.com)
Source: NaturalNews.com - February 20, 2019 Category: Consumer Health News Source Type: news

Study: Glyphosate-Based Herbicide Exposure Increases Cancer Risk By 41 Percent
BERKELEY, Calif. - A team of researchers led by a scientist at the University of California Berkeley released a study on Feb. 5 that concludes that "the overall meta-relative risk" of non-Hodgkin lymphoma (NHL) in a person exposed to glyphosate-based herbicides (GBHs) is 41 percent higher than in those who are not exposed to the chemical. (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - February 19, 2019 Category: Medical Law Source Type: news

Common Weed Killer Glyphosate Increases Cancer Risk By 41%, Study Says
(CNN) — Glyphosate, an herbicide that remains the world’s most ubiquitous weed killer, raises the cancer risk of those exposed to it by 41%, a new analysis says. Researchers from the University of Washington evaluated existing studies into the chemical — found in weed killers including Monsanto’s popular Roundup — and concluded that it significantly increases the risk of non-Hodgkin lymphoma (NHL), a cancer of the immune system. “All of the meta-analyses conducted to date, including our own, consistently report the same key finding: exposure to GBHs (glyphosate-based herbicides) are asso...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - February 15, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN weed killer Source Type: news

Weedkiller 'raises risk of non-Hodgkin lymphoma by 41%'
Study says evidence ‘supports link’ between exposure to glyphosate and increased riskSign up for the US morning briefing for a fresh perspectiveA broadnew scientific analysis of the cancer-causing potential of glyphosate herbicides, the most widely used weedkilling products in the world, has found that people with high exposures to the popular pesticides have a 41% increased risk of developing a type of cancer called non-Hodgkin lymphoma.The evidence “supports a compelling link” between exposures to glyphosate-based herbicides and increased risk for non-Hodgkin lymphoma (NHL), the authors concluded,...
Source: Guardian Unlimited Science - February 14, 2019 Category: Science Authors: Carey Gillam Tags: Monsanto Agriculture Science Business Cancer Herbicides Environment Health Source Type: news

Weedkiller chemical increases the risk of cancer 'by up to 41 per cent', study finds
Researchers led by the University of California Berkeley have said high exposure to the weedkiller glyphosate could cause non-Hodgkin lymphoma cancer. (Source: the Mail online | Health)
Source: the Mail online | Health - February 14, 2019 Category: Consumer Health News Source Type: news

Exposure to weed killing products increases risk of cancer by 41% – study
Evidence ‘supports link’ between exposures to glyphosate herbicides and increased risk for non-Hodgkin lymphomaA broadnew scientific analysis of the cancer-causing potential of glyphosate herbicides, the most widely used weed killing products in the world, has found that people with high exposures to the popular pesticides have a 41% increased risk of developing a type of cancer called non-Hodgkin lymphoma.The evidence “supports a compelling link” between exposures to glyphosate-based herbicides and increased risk for non-Hodgkin lymphoma (NHL), the authors concluded, though they said the specific n...
Source: Guardian Unlimited Science - February 14, 2019 Category: Science Authors: Carey Gillam Tags: Monsanto Agriculture Science Business Cancer Herbicides Environment Health Source Type: news

Glyphosate MDL Plaintiffs Present Exhibit About Monsanto's Lack Of Testing
SAN FRANCISCO - The plaintiffs in the multidistrict litigation for the herbicide Roundup on Jan. 25 filed exhibits in California federal court that are documents from a separate glyphosate case in which Monsanto Co. admits that it has not conducted a study specifically designed to examine if an association exists between glyphosate exposure and non-Hodgkin lymphoma (In re: Roundup Products Liability Litigation, MDL No. 2741, N.D. Calif.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - February 5, 2019 Category: Medical Law Source Type: news

Medical News Today: Everything you need to know about R-CHOP
R-CHOP chemotherapy uses a combination of five different drugs to treat specific types of cancer, including non-Hodgkin lymphoma. Learn more about how this treatment works and the potential side effects here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 23, 2019 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Cerebellar Large B-cell Lymphoma: A Case Report Cerebellar Large B-cell Lymphoma: A Case Report
This case report reviews the diagnosis, pathophysiology and management of primary central nervous system lymphoma, an aggressive non-Hodgkin lymphoma.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 9, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Allergan Halts Sales in Europe of Textured Breast Implants Linked to Rare Cancer
The company ’ s product, in use worldwide, has been under scrutiny since women began developing a type of lymphoma. (Source: NYT Health)
Source: NYT Health - December 19, 2018 Category: Consumer Health News Authors: DENISE GRADY Tags: Implants Breasts Medical Devices Plastic Surgery Non-Hodgkin's Lymphoma France Allergan Inc Cancer Recalls and Bans of Products Europe Source Type: news

Impact of Checkpoint Blockade Therapy on Subsequent Treatment in Non-Hodgkin Lymphoma Patients
Research presented at ASH 2018 examined whether checkpoint blockade therapy sensitizes patients with relapsed/refractory NHL to consequent treatment. (Source: CancerNetwork)
Source: CancerNetwork - December 6, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

Medical News Today: Does HIV increase cancer risk?
HIV can weaken a person ’s immune system, which can increase the risk of certain types of cancer. Such cancers include Kaposi’s sarcoma, non-Hodgkin lymphoma, and cervical, lung, anal, and oral cancer. However, effective treatment can significantly reduce the risk of developing these cancers. Learn more here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 4, 2018 Category: Consumer Health News Tags: HIV and AIDS Source Type: news

ASH: High Response to Tx After Checkpoint Blockade in NHL, HL
MONDAY, Dec. 3, 2018 -- For heavily pretreated patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL), response rates are high for treatment subsequent to checkpoint blockade therapy (CBT), according to two... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 3, 2018 Category: Pharmaceuticals Source Type: news

Genetically engineered immune cells show promise for fighting relapsed blood cancer
(UNC Lineberger Comprehensive Cancer Center) At the 60th Annual American Society of Hematology Annual Meeting in San Diego on Monday, UNC Lineberger Comprehensive Cancer Center researchers presented preliminary results from a clinical study of an investigational cellular immunotherapy for Hodgkin lymphoma and non-Hodgkin lymphoma expressing the CD30 protein marker. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 3, 2018 Category: Cancer & Oncology Source Type: news

Global trial shows CAR T therapy can lead to durable remissions in non-Hodgkin's lymphoma
(University of Pennsylvania School of Medicine) In an update to a global clinical trial stretching from Philadelphia to four continents, the chimeric antigen receptor (CAR) T cell therapy Kymriah ® (tisagenlecleucel, formerly CTL019) led to long-lasting remissions in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 1, 2018 Category: International Medicine & Public Health Source Type: news

Non-Hodgkin Lymphoma | Medscape Non-Hodgkin Lymphoma | Medscape
Non-Hodgkin lymphoma is the fifth most common cancer in the United States, accounting for about 4% of all malignancies in both men and women. The disease comprises a variety of cancers of the lymphatic system exclusive of Hodgkin lymphoma. (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 30, 2018 Category: Consumer Health News Tags: Resource Center Source Type: news

Truxima Approved as First Biosimilar to Non-Hodgkin's Lymphoma Drug
Title: Truxima Approved as First Biosimilar to Non-Hodgkin's Lymphoma DrugCategory: Health NewsCreated: 11/28/2018 12:00:00 AMLast Editorial Review: 11/29/2018 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - November 29, 2018 Category: Cancer & Oncology Source Type: news

FDA approves first biosimilar to Roche cancer drug Rituxan
Celltrion Inc's Truxima on Wednesday became the first biosimilar to Roche Holding AG's $7-billion-per-year cancer drug Rituxan to be approved in the United States to treat non-Hodgkin's lymphoma. (Source: Reuters: Health)
Source: Reuters: Health - November 29, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

First Biosimilar Rituximab for Lymphoma Approved in US First Biosimilar Rituximab for Lymphoma Approved in US
Truxima, designed for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin lymphoma, can be used as a single agent or in combination with chemotherapy.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 28, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA approves first biosimilar to Roche's cancer drug Rituxan
Celltrion Inc's Truxima on Wednesday became the first biosimilar to Roche Holding AG's $7-billion-per-year cancer drug Rituxan to be approved in the United States to treat non-Hodgkin's lymphoma. (Source: Reuters: Health)
Source: Reuters: Health - November 28, 2018 Category: Consumer Health News Tags: healthNews Source Type: news